Document is current
Any future updates will be listed below
-
Authors
Yu, Xiao
Cheng, Xinran
Wei, Haiyan
Xu, Xu
Gong, Chunxiu
Li, Guimei
Yao, Hui
Zhou, Li
Zhong, Yan
Yang, Yu
Luo, Feihong
Zhang, Yining
Huang, Frank
Shi, Xiaofeng
Cabri, Patrick
Luo, Xiaoping
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05029622 at ClinicalTrials.govDocuments that mention this clinical trial
A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty
https://doi.org/10.1007/s12325-024-02991-x
-
Funding
Funding for this research was provided by:
Ipsen
- License Information
-
More Information
Article History
Received: 13 June 2024
Accepted: 5 September 2024
First Online: 16 October 2024
Declarations
:
: Xiao Yu, Xinran Cheng, Haiyan Wei, Xu Xu, Chunxiu Gong, Guimei Li, Hui Yao, Li Zhou, Yan Zhong, Yu Yang, Feihong Luo, and Yining Zhang have no competing interests to disclose. Frank Huang, Xiaofeng Shi, and Patrick Cabri are employees of Ipsen. Xiaoping Luo has no competing interests to disclose.
: The study was conducted under the provisions of the Declaration of Helsinki, in accordance with International Conference on Harmonization (ICH), Consolidated Guideline on Good Clinical Practice (GCP) and in compliance with independent ethics committee and informed consent regulations. The study protocol, amendments, and informed consent form and updates were reviewed and approved by an ethics committee prior to commencement of the study, and during the study where applicable. Written informed consent was acquired from one or both of each participant’s parents or guardians, and signed approval was obtained from the child when applicable, prior to study entry.
